F8A1: A Potential Drug Target and Biomarker for Huntingtin-Associated Protein in Cancer

Target Name: F8A1

NCBI ID: G8263

F8A1

F8A1: A Potential Drug Target and Biomarker for Huntingtin-Associated Protein in Cancer

Introduction

Huntingtin-associated proteins (HAPs) are a family of transmembrane proteins that play crucial roles in various cellular processes, including DNA replication, apoptosis, and cell-cell adhesion. The F8A1 protein, also known as HAP-F8A1, is a 40-kDa protein that is expressed in various tissues and cells, including cancer cells. The identification and characterization of potential drug targets and biomarkers for HAPs, such as F8A1, could lead to new therapeutic approaches for cancer treatment.

F8A1: Structure and Function

The F8A1 protein is a 40-kDa protein that contains 116 amino acid residues. It has a molecular weight of 46 kDa and a calculated pI of 1.55 (pI is the protein's isoelectric point). F8A1 is predominantly localized to the cytoplasm and has a partial localization to the endoplasmic reticulum (ER). F8A1 has a monophosphorylated state at its amino terminal tail, which is involved in protein-protein interactions and may contribute to its function in cell signaling pathways.

Functional characterization of F8A1 has shown that it has various functions, including promoting DNA replication, influencing cell apoptosis, and regulating cell-cell adhesion. F8A1 has been shown to play a role in the regulation of cell cycle progression, specifically in the G1 phase, by preventing the phosphorylation of a specific protein called p21 (CDK4 kinase), which is involved in cell growth and cycle progression.

Additionally, F8A1 has been shown to influence the apoptosis process, which is a critical event in cancer development. F8A1 has been shown to promote the execution of apoptosis in cancer cells by activating the B-cell lymphoma 1 (Bcl-1) gene, which encodes a protein that can inhibit apoptosis.

F8A1 has also been shown to regulate cell-cell adhesion, which is a critical process for maintaining tissue structure and function. F8A1 has also been shown to play a role in the regulation of tight junction formation in epithelial cells, which are responsible for maintaining tissue structure and barrier function.

Drug Target Potential

The drug targeting of F8A1 is an attractive approach for cancer treatment, as it has been shown to play a critical role in various cellular processes that are involved in cancer development. F8A1 has been shown to be a potential drug target by various methods, including its involvement in cell signaling pathways, its expression in various tissues, and its involvement in cancer development.

One potential drug target for F8A1 is the inhibition of its activity, as this could lead to the inhibition of its functions and the regression of cancer development. The inhibition of F8A1 activity could be achieved through various methods, including inhibition of its phosphorylation, inhibition of its translation, or inhibition of its activity by binding to a specific protein or compound that targets its function.

Another potential drug target for F8A1 is the inhibition of its role in promoting DNA replication, as this could lead to the inhibition of its involvement in the regulation of cell cycle progression and the inhibition of its contribution to cancer development. The inhibition of F8A1's role in DNA replication could be achieved through various methods, including inhibition of its activity by binding to a specific DNA replication complex component or by inhibiting its activity by binding to a specific DNA replication inhibitor.

Biomarker Potential

F8A1 has also been shown to be a potential biomarker for cancer, as its expression has been shown to be associated with various cancer outcomes, including poor prognosis and recurrence. The detection and quantification of F8A1 expression in cancer cells could be

Protein Name: Coagulation Factor VIII Associated 1

Functions: RAB5A effector molecule that is involved in vesicular trafficking of early endosomes (PubMed:16476778). Mediates the recruitment of HTT by RAB5A onto early endosomes. The HTT-F8A1/F8A2/F8A3-RAB5A complex stimulates early endosomal interaction with actin filaments and inhibits interaction with microtubules, leading to the reduction of endosome motility (PubMed:16476778)

The "F8A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about F8A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets